Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quigley

This article was originally published in The Tan Sheet

Executive Summary

Hi-Tech Pharmacal/Health Care Products' Nasal-Ease product infringes Quigley's Cold-Eeze and Kids-Eeze marks, Doylestown, Penn.-based Quigley alleges in a lawsuit filed March 24 in Philadelphia federal court. Hi-Tech's use of the Nasal-Ease name is "likely to cause confusion, or to cause mistake or to deceive," the suit maintains. In addition to trademark infringement, the suit alleges false advertising under the Lanham Act, unfair competition and false designation of origin and common law unfair competition. Quigley takes issue with Hi-Tech's reference in ads to studies examining the effect of zinc on the common cold, including the Cleveland Clinic study of 1996 and the 1993 Dartmouth study, both of which support the use of zinc to reduce the duration of the common cold. Health Care Products says the suit is without merit. Cold-Eeze has been presented with a Edison gold award for best new product by the American Marketing Association. The award was selected by a panel of 3,500 senior marketing and advertising execs...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel